SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
APOLLO: PHASE 3 RANDOMIZED STUDY OF SUBCUTANEOUS DARATUMUMAB PLUS
POMALIDOMIDE AND DEXAMETHASONE (D-PD) VERSUS POMALIDOMIDE AND
DEXAMETHASONE (PD) ALONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE
DISCLOSURES POSTER 14
MYELOMA (RRMM)
Meletios A. Dimopoulos1, Evangelos Terpos1, Mario Boccadoro2, Sosanna Delimpasi3, Meral Beksac4,
Eirini Katodritou5, Philippe Moreau6, Luca Baldini7, Argiris Symeonidis8, Jelena Bila9, Albert Oriol10,
Maria-Victoria Mateos11, Hermann Einsele12, Ioannis Orfanidis13, Tahamtan Ahmadi14, Jon Ukropec15,
Tobias Kampfenkel16, Jordan M. Schecter17, Yanping Qiu18, Himal Amin17, Jessica Vermeulen16, Robin
Carson19 and Pieter Sonneveld20
(1)School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
(2)Division of Hematology - Department of Molecular Biotechnology and Health Sciences - University
of Torino, Torino, Italy
(3)Hematology-Lymphomas Dept and BMT Unit, Evangelismos, General Hospital of Athens, Athens,
Greece
(4)Department of Hematology, Ankara University, Ankara, Turkey
(5)Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
(6)University Hospital Hôtel-Dieu, Nantes, France
(7)Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy,
(8)Department of Internal Medicine, Division of Hematology, University of Patras, Medical School,
Patras, Greece
(9)University of Belgrade, Belgrade, Serbia
(10)Institut Català d’Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
(11)University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca,
Spain
(12)Würzburg University Medical Centre, Würzburg, Germany
(13)Health Data Specialists S.A, Dublin, Ireland
(14)Genmab US, Inc., Princeton, New Jersey, USA
(15)Janssen Global Medical Affairs, LLC, Horsham, PA
(16)Janssen Research & Development, LLC, Leiden, Netherlands
(17)Janssen Research & Development, Raritan, NJ
(18)Janssen Research & Development, Beijing, China
(19)Janssen Research & Development, LLC, Spring House, PA
(20)Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam,
Netherlands
Objectives
Daratumumab is an anti-CD38 approved for the treatment of RRMM. Subcutaneous (SC) formulation
of daratumumab has a similar safety profile as intravenous daratumumab and is approved in the US,
EU, Canada, and Korea. D-Pd is approved in the US for RRMM patients with ≥2 prior lines of therapy
(PL), including lenalidomide and a proteasome inhibitor (PI). The phase 3 APOLLO (NCT03180736)
study evaluated daratumumab SC plus Pd vs Pd in patients with RRMM.
Methods
Patients had RRMM and received ≥1 PL including lenalidomide and a PI, responded to prior treatment,
and progressed on/after last regimen; patients with only 1 PL were required to be lenalidomide-refractory.
Prior anti-CD38 or pomalidomide was not permitted. Patients were randomized 1:1 to Pd ±